

RELIATech GmbH
Lindener Str. 15
38300 Wolfenbüttel
Germany

Tel.: +49 5331 8586 987
Fax: +49 5331 8586 989
Email: info@reliatech.de
Web: www.reliatech.de

Recombinant Human sDLL-1

Description: Human sDLL-1 comprises the extracellular signaling domain of DLL1, a member of a structurally-related family of single-pass type I trans-membrane proteins that serve as ligands for Notch receptors. It is expressed in the heart and pancreas, and to a lesser extent in various other tissues. DLL-1 functions to specifically activate the Notch-1 and Notch-2 receptors. The Notch signaling pathway regulates endothelial-cell differentiation, proliferation and apoptosis, and is essential for the development, maintenance and remodeling of the vascular system. DLL-1 suppresses differentiation of hematopoietic progenitor cells into the B-cell lineage while promoting differentiation to T-cell and NK cell precursors. Recombinant human sDLL-1 is a 57-60 kDa glycoprotein containing 522 amino-acid residues.

Source:	293 T cells
Molecular Weight:	57-60 kDa
Purity:	> 95%, by SDS-PAGE and HPLC analysis
Endotoxin level:	< 0.1 ng per µg of sDLL-1
Formulation:	lyophilised

Biological Activity: Determined by the dose dependent growth suppression of the human acute monocytic leukemia cell line, THP-1. sDLL-1 inhibits the proliferation in THP-1 cells using a concentration of 3-5 µg/ml.

Stability: The lyophilized protein is stable for at least 2 years from date of receipt at -20°C. Reconstituted sDLL-1 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20°C. **Avoid repeated freeze/thaw cycles.**

Usage: Human sDLL-1 is offered for research use. Not for drug use. **Not for human use!**

Catalogue number: S01-060

Size: 25 µg